Open AccessDoes Nebivolol Prevent Contrast‐Induced Nephropathy in Humans?
Author(s) -
Günebakmaz Özgür,
Kaya Mehmet G.,
Koc Fatih,
Akpek Mahmut,
Kasapkara Ahmet,
Inanc M. Tugrul,
Yarlioglues Mikail,
Calapkorur Bekir,
Karadag Zakir,
Oguzhan Abdurrahman
Publication year - 2012
Publication title -
clinical cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.263
H-Index - 72
eISSN - 1932-8737
pISSN - 0160-9289
DOI - 10.1002/clc.21013
Subject(s) - medicine , nebivolol , contrast induced nephropathy , creatinine , renal function , nephropathy , statistical significance , clinical endpoint , urology , gastroenterology , anesthesia , surgery , randomized controlled trial , blood pressure , endocrinology , diabetes mellitus
Background: An experimental study showed that nebivolol is an effective agent in contrast‐induced nephropathy (CIN) prophylaxis. Hypothesis: We hypothesized that prophylactic nebivolol use had protective effects on renal function in human beings subjected to iodinated contrast agent since it has vasodilatory effect and antioxidant properties. Methods: The present study enrolled 120 patients scheduled for coronary angiography and ventriculography. All patients were hydrated with intravenous isotonic saline. The patients in group I received 600 mg N‐acetylcysteine every 12 hours for 4 days. The patients in group II received 5 mg nebivolol every 24 hours for 4 days. The patients in group III were only hydrated. The primary endpoint was the occurrence of CIN. The secondary endpoint was the change in serum creatinine (Cr) levels at 2 days and 5 days after the contrast exposure. Results: Nine (22.5%) patients in group I developed CIN, as did 8 patients (20.0%) in group II and 11 patients (27.5%) in group III ( P = 0.72). Changes in mean Cr level from baseline to day 2 were not statistically significant in all groups. However, we detected a statistically significant increase in mean Cr levels at day 5 compared with baseline levels in group I and group III (from 1.42 ± 0.13 to 1.52 ± 0.26, p2 = 0.02; and from 1.43 ± 0.14 to 1.55 ± 0.30, p2 = 0.01, respectively). Although an increase was detected in mean Cr level from baseline to the 5‐day Cr level in group II, this did not reach statistical significance (from 1.40 ± 0.12 to 1.48 ± 0.23, P = 0.06). Conclusions: Pretreatment with nebivolol is protective against nephrotoxic effects of contrast media. © 2012 Wiley Periodicals, Inc. The authors have no funding, financial relationships, or conflicts of interest to disclose.